Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 370.53 Billion KRW | -3.46% |
| 2022 | 383.81 Billion KRW | 3.36% |
| 2021 | 371.34 Billion KRW | 8.16% |
| 2020 | 343.32 Billion KRW | 5.78% |
| 2019 | 324.57 Billion KRW | 8.18% |
| 2018 | 300.03 Billion KRW | 11.2% |
| 2017 | 269.81 Billion KRW | 3.13% |
| 2016 | 261.61 Billion KRW | 40.44% |
| 2015 | 186.28 Billion KRW | -12.05% |
| 2014 | 211.79 Billion KRW | 43.37% |
| 2013 | 147.73 Billion KRW | 0.87% |
| 2012 | 146.46 Billion KRW | 3.75% |
| 2011 | 141.16 Billion KRW | 1.93% |
| 2010 | 138.48 Billion KRW | -6.23% |
| 2009 | 147.68 Billion KRW | 28.86% |
| 2008 | 114.61 Billion KRW | -4.72% |
| 2007 | 120.28 Billion KRW | -7.37% |
| 2006 | 129.86 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 82.7 Billion KRW | 5.37% |
| 2024 Q1 | 78.49 Billion KRW | -24.69% |
| 2023 Q4 | 104.22 Billion KRW | 3.57% |
| 2023 Q1 | 80.32 Billion KRW | -20.57% |
| 2023 Q3 | 100.63 Billion KRW | 17.89% |
| 2023 Q2 | 85.35 Billion KRW | 6.27% |
| 2023 FY | 370.53 Billion KRW | -3.46% |
| 2022 Q1 | 85.69 Billion KRW | -19.73% |
| 2022 FY | 383.81 Billion KRW | 3.36% |
| 2022 Q4 | 101.12 Billion KRW | -11.18% |
| 2022 Q3 | 113.85 Billion KRW | 36.94% |
| 2022 Q2 | 83.14 Billion KRW | -2.98% |
| 2021 Q2 | 81.56 Billion KRW | -0.64% |
| 2021 Q1 | 82.08 Billion KRW | -5.63% |
| 2021 FY | 371.34 Billion KRW | 8.16% |
| 2021 Q4 | 106.76 Billion KRW | 5.77% |
| 2021 Q3 | 100.93 Billion KRW | 23.76% |
| 2020 Q2 | 82.06 Billion KRW | 14.55% |
| 2020 Q4 | 86.97 Billion KRW | -15.26% |
| 2020 Q3 | 102.63 Billion KRW | 25.07% |
| 2020 Q1 | 71.64 Billion KRW | -11.12% |
| 2020 FY | 343.32 Billion KRW | 5.78% |
| 2019 Q1 | 76.97 Billion KRW | -2.74% |
| 2019 FY | 324.57 Billion KRW | 8.18% |
| 2019 Q4 | 80.6 Billion KRW | -10.27% |
| 2019 Q3 | 89.82 Billion KRW | 16.41% |
| 2019 Q2 | 77.16 Billion KRW | 0.25% |
| 2018 Q1 | 72.57 Billion KRW | 5.85% |
| 2018 FY | 300.03 Billion KRW | 11.2% |
| 2018 Q2 | 70.27 Billion KRW | -3.17% |
| 2018 Q3 | 78.03 Billion KRW | 11.04% |
| 2018 Q4 | 79.14 Billion KRW | 1.41% |
| 2017 Q3 | 80.55 Billion KRW | 32.56% |
| 2017 FY | 269.81 Billion KRW | 3.13% |
| 2017 Q1 | 59.92 Billion KRW | -1.71% |
| 2017 Q2 | 60.76 Billion KRW | 1.41% |
| 2017 Q4 | 68.56 Billion KRW | -14.88% |
| 2016 Q3 | 80.66 Billion KRW | 30.94% |
| 2016 Q4 | 60.96 Billion KRW | -24.41% |
| 2016 Q1 | 58.38 Billion KRW | 0.0% |
| 2016 Q2 | 61.6 Billion KRW | 5.52% |
| 2016 FY | 261.61 Billion KRW | 40.44% |
| 2015 Q3 | 68.12 Billion KRW | 12.02% |
| 2015 Q1 | 52.97 Billion KRW | -5.06% |
| 2015 FY | 186.28 Billion KRW | -12.05% |
| 2015 Q2 | 60.81 Billion KRW | 14.8% |
| 2014 Q2 | 45.77 Billion KRW | 24.1% |
| 2014 Q1 | 36.88 Billion KRW | -6.25% |
| 2014 FY | 211.79 Billion KRW | 43.37% |
| 2014 Q4 | 55.8 Billion KRW | -2.81% |
| 2014 Q3 | 57.41 Billion KRW | 25.44% |
| 2013 FY | 147.73 Billion KRW | 0.87% |
| 2013 Q1 | 37.48 Billion KRW | 1.11% |
| 2013 Q2 | 34.67 Billion KRW | -7.49% |
| 2013 Q3 | 36.83 Billion KRW | 6.23% |
| 2013 Q4 | 39.34 Billion KRW | 6.81% |
| 2012 Q1 | 34.51 Billion KRW | -0.7% |
| 2012 Q2 | 36.35 Billion KRW | 5.31% |
| 2012 Q3 | 35.56 Billion KRW | -2.17% |
| 2012 FY | 146.46 Billion KRW | 3.75% |
| 2012 Q4 | 37.06 Billion KRW | 4.24% |
| 2011 Q2 | 35.13 Billion KRW | 3.5% |
| 2011 Q1 | 33.94 Billion KRW | -1.44% |
| 2011 FY | 141.16 Billion KRW | 1.93% |
| 2011 Q4 | 34.76 Billion KRW | -5.42% |
| 2011 Q3 | 36.75 Billion KRW | 4.61% |
| 2010 Q3 | 34.98 Billion KRW | -0.39% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 138.48 Billion KRW | -6.23% |
| 2010 Q2 | 35.11 Billion KRW | 0.0% |
| 2010 Q4 | 34.43 Billion KRW | -1.55% |
| 2009 Q1 | 23.96 Billion KRW | -25.68% |
| 2009 FY | 147.68 Billion KRW | 28.86% |
| 2009 Q4 | 34.35 Billion KRW | 5.85% |
| 2009 Q3 | 32.45 Billion KRW | -7.39% |
| 2009 Q2 | 35.04 Billion KRW | 46.26% |
| 2008 Q4 | 32.24 Billion KRW | 0.76% |
| 2008 FY | 114.61 Billion KRW | -4.72% |
| 2008 Q3 | 31.99 Billion KRW | 21.16% |
| 2008 Q2 | 26.4 Billion KRW | 22.17% |
| 2008 Q1 | 21.61 Billion KRW | -34.08% |
| 2007 Q2 | 33.27 Billion KRW | 0.0% |
| 2007 Q4 | 32.79 Billion KRW | 0.57% |
| 2007 FY | 120.28 Billion KRW | -7.37% |
| 2007 Q3 | 32.6 Billion KRW | -2.0% |
| 2006 FY | 129.86 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -170.052% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 67.267% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 41.963% |
| HANDOK Inc. | 522.74 Billion KRW | 29.116% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -173.717% |
| Yuhan Corporation | 1858.98 Billion KRW | 80.068% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 44.195% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -613.189% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 75.147% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -174.656% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -318.244% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -118.519% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -65.082% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -170.052% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -374.724% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -145.273% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -324.132% |
| JW Holdings Corporation | 928.07 Billion KRW | 60.074% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 38.322% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 77.804% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 50.498% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -85.057% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -104.986% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -88.717% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 48.989% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -170.052% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 75.533% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 73.058% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 50.498% |
| Yuhan Corporation | 1858.98 Billion KRW | 80.068% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 53.375% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -57.741% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 37.679% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 50.498% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -26.841% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -32.836% |
| CKD Bio Corp. | 160.35 Billion KRW | -131.076% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 29.683% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -2.611% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -60.828% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -85.057% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 57.883% |
| Boryung Corporation | 859.62 Billion KRW | 56.895% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -194.245% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 0.0% |
| JW Lifescience Corporation | 206.86 Billion KRW | -79.124% |